Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.63 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.63 |
| ▸ | TNF | P01375 | 2/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | IL1B | P01584 | 1/20 | 0.63 |
| ▸ | MAP1LC3B | Q9GZQ8 | 7/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.50 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18270885 | 1.00 | CRBN (0.65) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL19611895 | 1.00 | CRBN (0.65) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL2032577 | 0.93 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL2037171 | 0.93 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL476914 | 0.93 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL30009197 | 0.93 | CRBN (0.75) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL25571498 | 0.87 | CRBN (0.56) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL19612000 | 0.86 | CRBN (0.86) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL19612001 | 0.86 | CRBN (0.86) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL19612009 | 0.86 | CRBN (0.62) | CRBNIKZF3DDB1IKZF1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352338-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-10844039-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10144745-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-9938302-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017201069-A1 | OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201069-A1 | OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS | BIOTHERYX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144745-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885DDB1 2485/4885 |
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | CRBN 1873/4885IKZF3 645/4885DDB1 293/4885 |
| US-10562917-B2 | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885DDB1 2485/4885 |
| US-10844039-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | CRBN 1873/4885IKZF3 645/4885DDB1 293/4885 |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | CRBN 1873/4885IKZF3 645/4885DDB1 293/4885 |
| US-20170333443-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885DDB1 2485/4885 |
| US-20170334932-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885DDB1 2485/4885 |
| US-20190276474-A1 | CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, CKS1B | CRBN 176/4885IKZF3 1/4885DDB1 2485/4885 |
| US-11352338-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | CRBN 1873/4885IKZF3 645/4885DDB1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.